NCT06913634View on ClinicalTrials.gov

Study to Evaluate the Long- Term Safety and Efficacy of Luspatercept in Subjects Who Received at Least One Dose of Luspatercept in the Compassionate Use Phase

Active, not recruitingOBSERVATIONAL
Enrollment

140

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

June 30, 2026

Conditions
Thalassemia Major
Interventions
DRUG

Luspatercept (ACE-536)

Luspatercept (ACE-536)

Trial Locations (1)

09121

University of Cagliari, Ospedale Pediatrico Microcitemico, via Jenner sn, 09121 Cagliari -, Cagliari

All Listed Sponsors
lead

Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia

OTHER